All Resources

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more|View

Access to Medicine • December 01, 2021

Canadian public insurance plans and delays in patient access to innovative medicines

Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to…

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • August 31, 2021

PMPRB Notice and Comment Response

Learn more|View

Access to Medicine • August 06, 2021

2022 Federal Pre-Budget Consultation

Learn more|View

Vaccine Equity • March 12, 2021

ISED Consultation on Biomanufacturing

Learn more|View

Patented Medicine Prices Review Board (PMPRB) • August 04, 2020

IMC Response to PMPRB 2020 Draft Guidelines

Learn more|View

July 24, 2020

Explaining Public Reimbursement Delays for New Medicines for Canadian Patients – 8.5×11

Learn more|View

Access to Medicine • June 30, 2020

Explaining Public Reimbursement Delays for New Medicines for Canadian Patients

Learn more|View

January 30, 2020

2019 Annual Report

Learn more|View

June 30, 2019

Cost Drivers Analysis of Private Drug Plans in Canada 2016-2018

Learn more|View

March 29, 2019

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans (March 2019)

Learn more|View

February 18, 2019

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications (February 2019)

Learn more|View